Dapagliflozin as an oral antihyperglycemic agent in the management of diabetes mellitus in patients with liver cirrhosis

Table 3 Comparison of clinical and laboratory investigations at baseline and 3 months later in control group

Parameter	Baseline, n = 100		3 months later, n = 100		Test of sig.
					t	P value
	Mean	SD	Mean	SD
Body weight in kg	95.86	19.13	84.60	14.21	4.725	0.0001
BMI in kg/m2	33.45	6.08	29.54	5.29	4.86	0.0001
SBP in mmHg	112.00	15.04	111.20	12.97	0.403	0.688
DBP in mmHg	70.80	10.22	70.80	9.18	0.0001	0.999
HbA1c as %	10.22	2.03	7.47	1.11	11.9	0.0001
Fasting blood sugar in mg/dL	299.26	77.57	174.74	63.29	12.438	0.0001
Triglycerides in mg/dL	240.04	78.18	221.62	51.48	1.968	0.050
Cholesterol in mg/dL	230.20	77.26	223.64	79.44	0.592	0.555
Creatinine in mg/dL	0.98	0.44	0.99	0.57	-0.144	0.886
MELD	12.46	5.11	12.32	5.60	0.185	0.854
MELD-Na	17.46	6.72	16.70	7.08	0.778	0.437
eGFR value in mL/min/1.73 m2	119.29	68.19	101.53	46.25	2.141	0.034
Uric acid in mg/dL	4.96	0.80	4.96	0.80	0.0001	0.999
AST in IU/L	74.56	90.09	67.58	81.21	0.575	0.566
ALT in IU/L	40.40	30.79	41.72	31.73	-0.299	0.766
GGT in IU/L	131.98	199.44	131.31	269.69	0.02	0.984
Serum Na in mmol/L	131.42	5.81	131.36	6.78	0.067	0.946
Serum K in mg/dL	4.33	0.62	4.19	0.45	1.857	0.065

ALT: Alanine transaminase; AST: Aspartate aminotransferase; BMI: Body mass index; DBP: Diastolic blood pressure; eGFR: Estimated glomerular filtration rate; GGT: gamma-glutamyl transferase; HbA1c: Hemoglobin A1c; K: Potassium; MELD: Model for end-stage liver disease; MELD-Na: Model for end-stage liver disease-sodium; NA: Sodium; SBP: Systolic blood pressure.